Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume -, Issue -, Pages 1-17
Publisher
Informa UK Limited
Online
2023-10-20
DOI
10.1080/14728214.2023.2273536
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
- (2023) Ian N Bruce et al. Lupus Science & Medicine
- JAK-STAT pathway inhibitors in dermatology
- (2023) Hélio Amante Miot et al. ANAIS BRASILEIROS DE DERMATOLOGIA
- Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers
- (2023) Lucy M Carter et al. BRITISH JOURNAL OF DERMATOLOGY
- Open-Label Phase 2 Pilot Study of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE)
- (2023) Sarah Alsukait et al. Journal of Drugs in Dermatology
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
- (2023) Eric F Morand et al. LANCET
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
- (2023) Michelle Petri et al. LANCET
- A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring
- (2023) Christeen Samuel et al. Dermatology and Therapy
- Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus
- (2023) François Chasset et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study
- (2022) Richard A Furie et al. Lupus Science & Medicine
- Biological impact of iberdomide in patients with active systemic lupus erythematosus
- (2022) Peter E Lipsky et al. ANNALS OF THE RHEUMATIC DISEASES
- Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus
- (2022) Joan T. Merrill et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation
- (2022) Allison C. Billi et al. Science Translational Medicine
- Multidimensional immune profiling of cutaneous lupus erythematosus in vivo stratified by patient responses to antimalarials
- (2022) Jay Patel et al. Arthritis & Rheumatology
- A Systematic Review of the Progression of Cutaneous Lupus to Systemic Lupus Erythematosus
- (2022) Paul Curtiss et al. Frontiers in Immunology
- Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus
- (2022) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
- (2022) Victoria P. Werth et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Burden of Living With Cutaneous Lupus Erythematosus
- (2022) Cristina Drenkard et al. Frontiers in Medicine
- Cutaneous Involvement in Systemic Lupus Erythematous: A Review for the Rheumatologist
- (2022) Courtney Stull et al. JOURNAL OF RHEUMATOLOGY
- Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
- (2022) Richard A. Furie et al. NEW ENGLAND JOURNAL OF MEDICINE
- An update on the management of refractory cutaneous lupus erythematosus
- (2022) Alice Verdelli et al. Frontiers in Medicine
- Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and Meta‐Analysis
- (2022) Rachel Kneeland et al. ARTHRITIS CARE & RESEARCH
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial
- (2022) Eric Morand et al. Arthritis & Rheumatology
- Phase 2, Randomized, Placebo-Controlled Trial of Dapirolizumab Pegol in Patients with Moderate-to-Severe Active Systemic Lupus Erythematosus
- (2021) Richard A Furie et al. RHEUMATOLOGY
- The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review
- (2021) Srita Chakka et al. Annals of Translational Medicine
- OP0132 EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY
- (2021) V. Werth et al. ANNALS OF THE RHEUMATIC DISEASES
- British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus (CLE) 2021
- (2021) D. O’Kane et al. BRITISH JOURNAL OF DERMATOLOGY
- Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus
- (2021) Qianjin Lu et al. JOURNAL OF AUTOIMMUNITY
- Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: a cohort study
- (2021) Emily Keyes et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Filgotinib or Lanraplenib in Moderate to Severe Cutaneous Lupus Erythematosus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study
- (2021) Victoria P Werth et al. RHEUMATOLOGY
- Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus
- (2021) Jodi L. Karnell et al. Science Translational Medicine
- Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
- (2021) David Isenberg et al. Arthritis & Rheumatology
- Cutaneous lupus concerns from the patient perspective: a qualitative study
- (2021) Daisy Yan et al. Lupus Science & Medicine
- Treatment of cutaneous lupus erythematosus
- (2020) Hong Shi et al. CURRENT OPINION IN RHEUMATOLOGY
- The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
- (2020) Eric Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Evaluating Change in Disease Activity Needed to Reflect Meaningful Improvement in Quality of Life for Clinical Trials in Cutaneous Lupus Erythematosus
- (2020) Srita Chakka et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus
- (2020) Scott A. Elman et al. JAMA Dermatology
- An evidence based approach to refractory cutaneous lupus erythematosus
- (2020) Robert Borucki et al. Arthritis & Rheumatology
- An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice
- (2020) Jay Patel et al. Current Rheumatology Reports
- Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
- (2019) Richard Furie et al. JOURNAL OF CLINICAL INVESTIGATION
- Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review
- (2019) François Chasset et al. DRUGS
- An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review
- (2019) William D. Shipman et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies
- (2019) Joerg Wenzel Nature Reviews Rheumatology
- Management of cutaneous manifestations of lupus erythematosus: A systematic review
- (2019) J.L. Fairley et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Molecular Profiling of Cutaneous Lupus Lesions Identifies Subgroups Distinct from Clinical Phenotypes
- (2019) Celine C. Berthier et al. Journal of Clinical Medicine
- IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study
- (2019) Frederic A Houssiau et al. ANNALS OF THE RHEUMATIC DISEASES
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus
- (2019) Eric F. Morand et al. NEW ENGLAND JOURNAL OF MEDICINE
- Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa
- (2018) Mrinal K Sarkar et al. ANNALS OF THE RHEUMATIC DISEASES
- A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
- (2018) Fengchun Zhang et al. ANNALS OF THE RHEUMATIC DISEASES
- Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study
- (2018) J H Hesselvig et al. BRITISH JOURNAL OF DERMATOLOGY
- Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study
- (2018) Lavanya Mittal et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study
- (2018) Elise Cesbron et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark
- (2018) M Prütz Petersen et al. LUPUS
- Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern United States: The Georgia Lupus Registry
- (2018) Cristina Drenkard et al. ARTHRITIS CARE & RESEARCH
- Increased myeloid dendritic cells and TNF-α expression predicts poor response to hydroxychloroquine in cutaneous lupus erythematosus
- (2018) Majid Zeidi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
- (2018) Ronald F van Vollenhoven et al. LANCET
- The Dual Nature of Type I and Type II Interferons
- (2018) Amanda J. Lee et al. Frontiers in Immunology
- Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus
- (2018) Rita Quelhas da Costa et al. JAMA Dermatology
- Type I Interferons in Autoimmune Disease
- (2018) Mary K. Crow et al. Annual Review of Pathology-Mechanisms of Disease
- JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus
- (2017) Anna Sophie Klaeschen et al. EXPERIMENTAL DERMATOLOGY
- Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus
- (2017) Renee Fruchter et al. JAMA Dermatology
- Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial
- (2017) N. Yokogawa et al. Arthritis & Rheumatology
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
- (2017) Richard Furie et al. Arthritis & Rheumatology
- Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
- (2017) William Stohl et al. Arthritis & Rheumatology
- Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
- (2016) Munther Khamashta et al. ANNALS OF THE RHEUMATIC DISEASES
- Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience
- (2016) Scott A. Kindle et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients
- (2016) Feriel Fennira et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)
- (2016) A. Kuhn et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)
- (2015) Kenneth C Kalunian et al. ANNALS OF THE RHEUMATIC DISEASES
- Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? A Retrospective Analysis of 34 Patients and a Review of the Literature
- (2015) Martin Klebes et al. DERMATOLOGY
- Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms
- (2015) A. Pellerin et al. EMBO Molecular Medicine
- Influence of smoking on the efficacy of antimalarials in cutaneous lupus: A meta-analysis of the literature
- (2015) François Chasset et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- From BILAG to BILAG-based combined lupus assessment—30 years on
- (2015) Claire-Louise Murphy et al. RHEUMATOLOGY
- Pathophysiology of cutaneous lupus erythematosus
- (2015) Jordan C Achtman et al. ARTHRITIS RESEARCH & THERAPY
- Brief Report: Responses to Rituximab Suggest B Cell-Independent Inflammation in Cutaneous Systemic Lupus Erythematosus
- (2015) Edward M. Vital et al. Arthritis & Rheumatology
- The classification and diagnosis of cutaneous lupus erythematosus
- (2014) Annegret Kuhn et al. JOURNAL OF AUTOIMMUNITY
- Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial
- (2014) Lauren Okon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cutaneous lupus erythematosus: Diagnosis and treatment
- (2013) L.G. Okon et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials
- (2013) Richard G. B. Langley et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus
- (2012) Johanna Sigges et al. AUTOIMMUNITY REVIEWS
- The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score
- (2012) I. Braunstein et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
- (2012) Josefina Cortés-Hernández et al. ARTHRITIS RESEARCH & THERAPY
- Impact of Smoking in Cutaneous Lupus Erythematosus
- (2011) Evan W. Piette ARCHIVES OF DERMATOLOGY
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
- (2011) Richard Furie et al. ARTHRITIS AND RHEUMATISM
- The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment
- (2011) K.M.A.C. Luijten et al. AUTOIMMUNITY REVIEWS
- Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden
- (2011) C.M. Grönhagen et al. BRITISH JOURNAL OF DERMATOLOGY
- Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome
- (2011) J. Cortés-Hernández et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus
- (2011) Md. Nazrul ISLAM et al. International Journal of Rheumatic Diseases
- Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus
- (2011) Bryan Gammon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Quality of life in cutaneous lupus erythematosus
- (2011) Rachel Klein et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
- (2011) Sandra V Navarra et al. LANCET
- Treatment of Cutaneous Lupus
- (2011) Aileen Y. Chang et al. Current Rheumatology Reports
- Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus
- (2010) A. Kuhn et al. LUPUS
- Incidence of Cutaneous Lupus Erythematosus, 1965-2005
- (2009) Olayemi Durosaro et al. ARCHIVES OF DERMATOLOGY
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
- (2009) Joan T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Cigarette Smoking and Cutaneous Damage in Systemic Lupus Erythematosus
- (2009) I. TURCHIN et al. JOURNAL OF RHEUMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started